A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis

Background Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Lokivetmab, a caninized anti‐canine IL‐31 monoclonal antibody, reduced pruritus and associated inflammatory skin lesions in a proof‐of‐concept study in dogs with AD. Hypothesis/Objectives The objective was to descri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Veterinary dermatology 2016-12, Vol.27 (6), p.478-e129
Hauptverfasser:	Michels, Gina M., Ramsey, Deborah S., Walsh, Kelly F., Martinon, Olivier M., Mahabir, Sean P., Hoevers, Jacquelien D., Walters, Rodney R., Dunham, Steven A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - immunology Dermatitis, Atopic - drug therapy Dermatitis, Atopic - veterinary Dog Diseases - drug therapy Dogs Dose-Response Relationship, Drug Double-Blind Method Interleukins - immunology Pruritus - drug therapy Pruritus - veterinary
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!